Failure to prescribe pneumocystis prophylaxis is associated with increased mortality, even in the cART era: results from the Treat Asia HIV observational database.
Abstract
BACKGROUND
Pneumocystis jiroveci pneumonia (PCP) prophylaxis is recommended for patients with CD4 counts of less than 200 cells/mm3.
This study examines the proportion of patients in the TREAT Asia HIV Observational Database (TAHOD) receiving PCP prophylaxis,
and its effect on PCP and mortality.
METHODS
TAHOD patients with prospective follow up had data extracted for prophylaxis using co-trimoxazole, dapsone or pentamidine.
The proportion of patients on prophylaxis was calculated for each calendar year since 2003 among patients with CD4 counts
of less than 200 cells/mm3. The effect of prophylaxis on PCP and survival were assessed using random-effect Poisson regression
models.
RESULTS
There were a total of 4050 patients on prospective follow up, and 90% of them were receiving combination antiretroviral therapy.
Of those with CD4 counts of less than 200 cells/mm3, 58% to 72% in any given year received PCP prophylaxis, predominantly
co-trimoxazole. During follow up, 62 patients developed PCP (0.5 per 100 person-years) and 169 died from all causes (1.36/100
person-years). After stratifying by site and adjusting for age, CD4 count, CDC stage and antiretroviral treatment, those without
prophylaxis had no higher risk of PCP, but had a significantly higher risk of death (incident rate ratio 10.8, p<0.001). PCP
prophylaxis had greatest absolute benefit in patients with CD4 counts of less than 50 cells/mm3, lowering mortality rates
from 33.5 to 6.3 per 100 person-years.
CONCLUSIONS
Approximately two-thirds of TAHOD patients with CD4 counts of less than 200 cells/mm3 received PCP prophylaxis. Patients without
prophylaxis had significantly higher mortality, even in the era of combination ART. Although PCP may be under-diagnosed, these
data suggest that prophylaxis is associated with important survival benefits.
Links
Authors
Lim PL, Zhou J, Ditangco RA, Law MG, Sirisanthana T, Kumarasamy N, Chen YM, Phanuphak P, Lee CK, Saphonn V, Oka S, Zhang F, Choi JY, Pujari S, Kamarulzaman A, Li PC, Merati TP, Yunihastuti E, Messerschmidt L, Sungkanuparph S, TREAT Asia HIV Observational Database
Institution
Tan Tock Seng Hospital, Singapore.
Source
Journal of the International AIDS Society 15: 2012 pg 1MeSH
AIDS-Related Opportunistic InfectionsAdult
Anti-HIV Agents
Antifungal Agents
Asia
CD4 Lymphocyte Count
Dapsone
Databases, Factual
Drug Therapy, Combination
Female
Follow-Up Studies
Humans
Male
Middle Aged
Pentamidine
Pneumocystis jirovecii
Pneumonia, Pneumocystis
Prospective Studies
Trimethoprim-Sulfamethoxazole Combination
Pub Type(s)
Journal ArticleResearch Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Language
eng
PubMed ID
22281054
Log In

